Sertaconazole
As of the edition of 20 October 2026, Sertaconazole is a small molecule: marketed, first approved in 1992 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Ertaczo
- First approved
- 1 March 1992 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Lacer Pharma; 3 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lacer Pharma | Acquired holder | 2023 to now |